KR102446310B1 - 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제 - Google Patents

경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제 Download PDF

Info

Publication number
KR102446310B1
KR102446310B1 KR1020217034294A KR20217034294A KR102446310B1 KR 102446310 B1 KR102446310 B1 KR 102446310B1 KR 1020217034294 A KR1020217034294 A KR 1020217034294A KR 20217034294 A KR20217034294 A KR 20217034294A KR 102446310 B1 KR102446310 B1 KR 102446310B1
Authority
KR
South Korea
Prior art keywords
amino
xaa
compound
peptide
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217034294A
Other languages
English (en)
Korean (ko)
Other versions
KR20220012840A (ko
Inventor
제임스 크너 패트릭
패트릭 피난 브라이언
디마치 리차드
린데로스 라르스
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Priority to KR1020217034342A priority Critical patent/KR20230029480A/ko
Publication of KR20220012840A publication Critical patent/KR20220012840A/ko
Application granted granted Critical
Publication of KR102446310B1 publication Critical patent/KR102446310B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020217034294A 2020-07-22 2021-07-22 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제 Active KR102446310B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217034342A KR20230029480A (ko) 2020-07-22 2021-07-22 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063055026P 2020-07-22 2020-07-22
US63/055,026 2020-07-22
EP20192414 2020-08-24
EP20192414.9 2020-08-24
US202163156988P 2021-03-05 2021-03-05
US63/156,988 2021-03-05
PCT/EP2021/070485 WO2022018186A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034342A Division KR20230029480A (ko) 2020-07-22 2021-07-22 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제

Publications (2)

Publication Number Publication Date
KR20220012840A KR20220012840A (ko) 2022-02-04
KR102446310B1 true KR102446310B1 (ko) 2022-09-23

Family

ID=77179985

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217034294A Active KR102446310B1 (ko) 2020-07-22 2021-07-22 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제
KR1020217034342A Ceased KR20230029480A (ko) 2020-07-22 2021-07-22 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217034342A Ceased KR20230029480A (ko) 2020-07-22 2021-07-22 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제

Country Status (15)

Country Link
US (4) US20220177538A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185607A1 (cg-RX-API-DMAC7.html)
JP (2) JP7581385B2 (cg-RX-API-DMAC7.html)
KR (2) KR102446310B1 (cg-RX-API-DMAC7.html)
CN (1) CN116157143A (cg-RX-API-DMAC7.html)
AU (1) AU2021312323A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000270A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184717A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000087A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000097A2 (cg-RX-API-DMAC7.html)
IL (1) IL299701A (cg-RX-API-DMAC7.html)
MX (1) MX2023000303A (cg-RX-API-DMAC7.html)
PE (1) PE20231841A1 (cg-RX-API-DMAC7.html)
TW (2) TW202315883A (cg-RX-API-DMAC7.html)
WO (1) WO2022018186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如glp—1之肽治療劑的口服投與
CN117646017A (zh) * 2023-11-02 2024-03-05 中国人民解放军海军军医大学 Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
TWI926512B (zh) 2023-11-30 2026-05-21 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
IL328247A (en) * 2023-11-30 2026-07-01 Novo Nordisk As Tri-agonists of GLP-1, GIP and amylin receptors
WO2025133045A1 (en) 2023-12-22 2025-06-26 Novo Nordisk A/S Fermentation process
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds
KR102991397B1 (ko) 2024-11-29 2026-07-21 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
KR20130083843A (ko) 2010-06-24 2013-07-23 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 디펩티드 연결된 약제
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
HUE064694T2 (hu) * 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
SI2864350T1 (en) 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
RS58039B1 (sr) * 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
DK3004155T3 (da) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015035419A1 (en) 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
WO2016198604A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
US20170112897A1 (en) 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
PE20210473A1 (es) 2018-05-04 2021-03-08 Novo Nordisk As Derivados de gip y usos de estos
KR20250044806A (ko) 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
ES3068975T3 (en) 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
AU2020256648B2 (en) * 2019-04-11 2026-01-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
CN110642935A (zh) 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Also Published As

Publication number Publication date
TWI801942B (zh) 2023-05-11
US20230120597A1 (en) 2023-04-20
PE20231841A1 (es) 2023-11-21
AU2021312323A1 (en) 2023-02-02
EP4185607A1 (en) 2023-05-31
BR112023000270A2 (pt) 2023-01-31
JP7581385B2 (ja) 2024-11-12
JP2023534131A (ja) 2023-08-08
JP2025020197A (ja) 2025-02-12
TW202208411A (zh) 2022-03-01
CN116157143A (zh) 2023-05-23
US20230272029A1 (en) 2023-08-31
US20220177538A1 (en) 2022-06-09
CA3184717A1 (en) 2022-01-27
MX2023000303A (es) 2023-02-09
WO2022018186A1 (en) 2022-01-27
TW202315883A (zh) 2023-04-16
KR20220012840A (ko) 2022-02-04
US11779648B2 (en) 2023-10-10
CL2023000087A1 (es) 2023-07-07
US20220125940A1 (en) 2022-04-28
IL299701A (en) 2023-03-01
KR20230029480A (ko) 2023-03-03
CO2023000097A2 (es) 2023-03-27

Similar Documents

Publication Publication Date Title
US11779648B2 (en) Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
US20230346961A1 (en) Glp-1 and gip receptor co-agonists
KR102379958B1 (ko) Gip 유도체 및 이의 용도
US20230391845A1 (en) Glp-1, gip and glucagon receptor triple agonists
JP7434616B2 (ja) プロドラッグおよびその使用
EP4240420A1 (en) Glp-1 prodrugs and uses hereof
CN118632867A (zh) Glp-1/gip受体共激动剂前药及其用途
EA049130B1 (ru) Коагонисты рецепторов glp-1 и gip, подходящие для пероральной доставки

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211022

PA0105 International application

Patent event date: 20211022

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211022

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20211022

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220321

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220706

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220919

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220920

End annual number: 3

Start annual number: 1

PG1601 Publication of registration